Treatment strategy of MCRC patients differs according to patient’s fitness (age, comorbidity), metastatic extension (liver-limited (L-L) or other/multiple metastatic sites (O/MM)), and KRAS2–4/NRAS2–4/BRAF15 genotype [9, 6, 15]. This evidence concerns the gene KRAS and Miyoshi myopathy.